相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy
Andre Pfob et al.
EUROPEAN JOURNAL OF CANCER (2021)
Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer
Yuhong Huang et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
The relationship between NFKB, HER2, ER expression and anthracycline-based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia
Indra et al.
ANNALS OF MEDICINE AND SURGERY (2021)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients
Shujun Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
Hanna Piotrzkowska-Wroblewska et al.
PLOS ONE (2019)
Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast Carcinoma
Luis A. Riba et al.
JOURNAL OF SURGICAL RESEARCH (2019)
Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy
Paula Cabrera-Galeana et al.
ONCOLOGIST (2018)
MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
Briete X. Z. Goorts et al.
BREAST CANCER RESEARCH (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Imaging Neoadjuvant Therapy Response in Breast Cancer
Amy M. Fowler et al.
RADIOLOGY (2017)
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
Jinglu Wang et al.
ONCOTARGET (2017)
A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound
Hadi Tadayyon et al.
SCIENTIFIC REPORTS (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice
H. Cain et al.
CLINICAL ONCOLOGY (2017)
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning
Stephanie N. Dorman et al.
MOLECULAR ONCOLOGY (2016)
Abstract P5-01-02: Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC)
JM Specht et al.
CANCER RESEARCH (2016)
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V. Bossuyt et al.
ANNALS OF ONCOLOGY (2015)
3 Multigene prognostic tests in breast cancer: past, present, future
Balazs Gyorffy et al.
BREAST CANCER RESEARCH (2015)
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Kwan Il Kim et al.
JOURNAL OF BREAST CANCER (2014)
Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
Juhasz-Boss Ingolf et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Richard Callaghan et al.
DRUG METABOLISM AND DISPOSITION (2014)
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta-Analysis
Fabian Pius Mghanga et al.
CLINICAL BREAST CANCER (2013)
Current approaches for neoadjuvant chemotherapy in breast cancer
Roisin M. Connolly et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy
Michael L. Marinovich et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review
M. B. I. Lobbes et al.
INSIGHTS INTO IMAGING (2013)
Mechanisms of chemoresistance in cancer stem cells
Lissa Nurrul Abdullah et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2013)
Breast cancer in the elderly-Should it be treated differently?
Petra Tesarova
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
Xu Cheng et al.
ACTA RADIOLOGICA (2012)
Response Evaluation in Patients With Colorectal Liver Metastases: RECIST Version 1.1 Versus Modified CT Criteria
Woo-Suk Chung et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2012)
Neoadjuvant therapy for ER-positive breast cancers
M. Colleoni et al.
ANNALS OF ONCOLOGY (2012)
Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis
Yuting Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients
Randal Croshaw et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Amit K. Tiwari et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer
Jason D. Keune et al.
AMERICAN JOURNAL OF SURGERY (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F] Fluorodeoxyglucose
Joerg Schwarz-Dose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
Gunter von Minckwitz et al.
BREAST CANCER RESEARCH (2008)
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy
Florentia Peintinger et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: Chemoresistance and prediction of response to drug therapy
S. Chuthapisith et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2006)
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
RJ Burcombe et al.
BRITISH JOURNAL OF CANCER (2005)
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
SJ Kim et al.
ANNALS OF ONCOLOGY (2004)
Apoptosis, chemoresistance, and breast cancer: Insights from the MCF-7 cell model system
R Simstein et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2003)
Measuring response in solid tumors: Comparison of RECIST and WHO response criteria
JO Park et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2003)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
Measuring the clinical response. What does it mean?
P Therasse
EUROPEAN JOURNAL OF CANCER (2002)
Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
M Schelling et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
